The AAV Vector Challenge With Selecta's Dr. Carsten Brunn

The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Audio version available here: https://www.bioprocessonline.com/doc/... Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast... Spotify - https://open.spotify.com/show/5NhjpDe... Google - https://podcasts.google.com/?q=busine...